What is GemPharmatech Co., Ltd.'s (688046.SS) StockRank?

MoatMap's StockRank for GemPharmatech Co., Ltd. (688046.SS) is 70/100, with a Buy signal. This is a composite score combining Quality (65), Value (24), and Momentum (69) factor ranks across MoatMap's 19,000+ stock universe.

Does GemPharmatech Co., Ltd. have an economic moat?

GemPharmatech Co., Ltd. (688046.SS) has a Quality factor score of 65/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is GemPharmatech Co., Ltd. a buy, hold, or sell?

MoatMap's current signal for GemPharmatech Co., Ltd. (688046.SS) is Buy, based on a StockRank of 70/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is GemPharmatech Co., Ltd. in?

GemPharmatech Co., Ltd. (688046.SS) operates in the Healthcare sector, specifically the Biotechnology industry (China).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

688046.SS

BUYREMOVE

GemPharmatech Co., Ltd. · Healthcare · China · $1.2B · Avg Vol: $13M/d

StockRank

P/E (TTM)

44.7x

ROE

7.2%

D/E

0.1x

Dividend %

1.2%

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

GemPharmatech is a Chinese preclinical CRO/CDMO specializing in genetically engineered mice models. While it has solid quality metrics, it faces severe geopolitical headwinds from Western legislative efforts (such as the Biosecure Act) targeting Chinese biotech service providers, destroying the near-term bull case.

COMPANY DESCRIPTION

GemPharmatech Co., Ltd. specializes in the R&D, production, and sale of genetically engineered mouse models (GEMMs) and preclinical CRO services. The company possesses one of the world's largest repositories of mouse models, creating a high barrier to entry through its proprietary genetic strains. It serves as a leading global supplier of specialized animal models for biomedical research and drug discovery.

FINANCIAL SUMMARY

Year	2022	2023	2024	2025	CAGR
Revenue	76M	92M	102M	117M	15.4%
EPS	0.06	0.06	0.04	0.05	-5.9%
Shares	410M	410M	410M	410M	0.0%
Debt	3M	18M	20M	43M	153.6%
Equity	292M	314M	315M	329M	4.0%
Op CF	16M	17M	13M	34M	28.9%
Inv CF	-147M	-3M	23M	-69M	—
Fin CF	150M	6M	-16M	4M	—

PRICE (1M)-13.3%

SMA 50SMA 200

$2.64

RSI (14)

29.5

52W High

$3.21

From 52W High

0.8%

SCORE BREAKDOWN

Quality

ROIC

7.3%64.6

ROE

7.2%63.4

GP/Assets

18.6%43.5

Op. Margin

24.9%88.2

FCF/Assets

2.7%60.5

Piotroski

—83.5

Int. Cover

28.1x78.5

D/E Ratio

0.11x64.1

Current Ratio

3.58x59.4

Value

P/E (TTM)

44.7x23.0

EV/EBITDA

25.2x14.1

P/FCF

700.7x11.6

P/B

3.1x38.4

P/S

8.8x28.7

Div Yield

1.2%34.4

Momentum

52W High %

82%77.5

RS 6M

5%79.9

SMA 50/200

1.10x79.3

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—N/A

Q Growth

57%78.5

FUNDAMENTALS

Market Cap

$1.2B

P/E (Forward)

—

Gross Margin

63.8%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 688046.SS are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
688046.SS	GemPharmatech Co., Ltd.(you)	$1.2B	70	BUY
301047.SZ	Sino Biological,Inc.	$1.1B	70	BUY
688105.SS	Nanjing Vazyme Biotech Co., Ltd	$1.1B	63	HOLD
300841.SZ	Chengdu Kanghua Biological Products Co., Ltd.	$917M	67	BUY
688253.SS	Innovita Biological Technology Co., Ltd.	$1.1B	58	HOLD
000990.SZ	Chengzhi Co., Ltd.	$1.7B	63	HOLD
605116.SS	Aurisco Pharmaceutical Co.,Ltd.	$1.2B	56	HOLD
688315.SS	Novogene Co., Ltd.	$870M	60	HOLD
688202.SS	Shanghai Medicilon Inc.	$1.2B	53	HOLD
002030.SZ	Daan Gene Co., Ltd.	$1.5B	57	HOLD

Peer medians: ROE 4.7% · P/E 27.6x · Gross margin 53.0%

GemPharmatech Co., Ltd. (688046.SS) — Stock Score Summary

GemPharmatech Co., Ltd. (688046.SS) has a MoatMap StockRank of 70/100 based on Quality (65/100), Value (24/100), and Momentum (69/100) factor scores. The current signal is BUY. GemPharmatech is a Chinese preclinical CRO/CDMO specializing in genetically engineered mice models. While it has solid quality metrics, it faces severe geopolitical headwinds from Western legislative efforts (such as the Biosecure Act) targeting Chinese biotech service providers, destroying the near-term bull case.

Key Financial Metrics

Price	$2.64
Market Cap	$1.2B
P/E (TTM)	44.70
Price/Book	3.08
Return on Equity	7.2%
Return on Invested Capital	7.3%
Debt/Equity	11.39
Gross Margin	63.8%
Operating Margin	24.9%
Revenue Growth	21.8%
Dividend Yield	1.2%
Free Cash Flow	$2M

GemPharmatech Co., Ltd. operates in the Biotechnology industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is GemPharmatech Co., Ltd.’s (688046.SS) StockRank?: MoatMap’s StockRank for GemPharmatech Co., Ltd. (688046.SS) is 70/100, with a Buy signal. It is a composite of Quality (65), Value (24), and Momentum (69) factor ranks across MoatMap’s 19,000+ stock universe.
Does GemPharmatech Co., Ltd. have an economic moat?: GemPharmatech Co., Ltd. (688046.SS) has a Quality factor score of 65/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is GemPharmatech Co., Ltd. a buy, hold, or sell?: MoatMap’s current signal for GemPharmatech Co., Ltd. (688046.SS) is Buy, based on a StockRank of 70/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is GemPharmatech Co., Ltd. in?: GemPharmatech Co., Ltd. (688046.SS) operates in the Healthcare sector, specifically the Biotechnology industry (China).